Skip to main content
. Author manuscript; available in PMC: 2023 Aug 19.
Published in final edited form as: ACS Chem Biol. 2022 Jul 14;17(8):2188–2200. doi: 10.1021/acschembio.2c00330

Figure 3. Remyelinating agents inhibit CYP51, EBP, and sterol 14-reductase.

Figure 3.

(A) Validated screening hits from Najm et al, 2015, with annotations of subsequently-established inhibitory activity for EBP, CYP51, or sterol 14-reductase. (B) GC-MS based quantification of lanosterol levels in OPCs treated with ketoconazole (2.5 μM), a known CYP51 inhibitor, and megestrol (13.4 μM) for 24 h. n2 wells per condition. (C) GC-MS based quantification of 14-dehydrozymostenol, zymostenol, and zymosterol levels in OPCs treated for 24 h with dicyclomine, propafenone, and haloperidol at 2 μM. S14R, sterol 14-reductase.